<DOC>
	<DOCNO>NCT00454584</DOCNO>
	<brief_summary>The purpose study compare efficacy safety CNTO 1275 etanercept patient moderate severe plaque psoriasis .</brief_summary>
	<brief_title>An Efficacy Safety Study CNTO 1275 Compared Etanercept Patients With Plaque Psoriasis</brief_title>
	<detailed_description>This multicenter , randomize ( study medication assign chance ) , active-controlled , parallel , 3-arm study . Patients randomly ( allocation treatment available chance ) assign 3:5:5 ratio receive one three treatment group . The three treatment group : Group 1 - CNTO 1275 45 mg dose week 0 4 , Group 2 - CNTO 1275 90 mg dose week 0 4 , Group 3 - Etanercept 50 mg two time per week week 12 . The total duration participant 64 week ( approximately 16 month ) . The active-controlled portion study Week 0 Week 12 efficacy safety etanercept 2 dose level CNTO 1275 evaluate . Treatment Week 12 dependent Physician 's Global Assessment ( PGA ) response Week 12 initial treatment assignment . Patients receive 2 subcutaneous injection CNTO 1275 ( either 45 90 mg dos ) twice weekly injection etanercept first twelve week study . Patients may receive two additional dos CNTO 1275 ( either 45 90 mg dos ) week 44 .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Ustekinumab</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Have diagnosis plaquetype psoriasis least 6 month prior study Have plaquetype psoriasis cover least 10 percentage total body surface area Have Psoriasis Area Severity Index ( PASI ) score 12 great Physician 's Global Assessment ( PGA ) score 3 great time first administration study drug Must suitable phototherapy systemic treatment psoriasis Have fail respond condition prevents use cyclosporine , methotrexate ( MTX ) psoralen plus ultraviolet light A ( PUVA ) Currently nonplaque form psoriasis Have current druginduced psoriasis Have use therapeutic agent target reduce interleukin12 ( IL12 ) IL23 ( Interleukins substance produce body immunological disease like psoriasis ) Have receive phototherapy systemic medications/treatments could affect psoriasis PASI evaluation ( include , limited , oral injectable corticosteroid , retinoids , 1,25 dihydroxy vitamin D3 analogue , psoralens , sulfasalazine , hydroxyurea , fumaric acid derivative ) within 4 week first administration study agent Have use biologic within previous 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>CNTO 1275</keyword>
	<keyword>Etanercept</keyword>
	<keyword>Immune diorder</keyword>
	<keyword>Skin disorder</keyword>
</DOC>